Status:
ENROLLING_BY_INVITATION
Carbonic Anhydrase Inhibitors and Carbonation: A Novel Approach to Reduce Soda Consumption
Lead Sponsor:
University of Arizona
Conditions:
Obesity
Eligibility:
All Genders
18-100 years
Phase:
EARLY_PHASE1
Brief Summary
Acetazolamide is a drug that is approved by the FDA for treating various conditions like epilepsy, altitude sickness, and glaucoma. Acetazolamide works by inhibiting an enzyme called carbonic anhydras...
Eligibility Criteria
Inclusion
- Age ≥ 18 years.
- Consumes on average ≥ 7 sodas per week
- Healthy and without a history of significant neurological, liver, renal, cardiac or pulmonary disease.
- No allergy to sulfa drugs or aspirin (contained in Alka Seltzer).
- Ability to provide informed consent.
Exclusion
- Healthy adults, UA students, UA faculty and staff
Key Trial Info
Start Date :
January 18 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2024
Estimated Enrollment :
44 Patients enrolled
Trial Details
Trial ID
NCT06110078
Start Date
January 18 2024
End Date
May 1 2024
Last Update
May 7 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
College of Medicine Phoenix U of Arizona
Phoenix, Arizona, United States, 85004